KR20090025497A - The cosmetics composition being contained pau d'arco, tabebuia avellanedae extracts and having the effects of antiphlogistic and abirritation of skin - Google Patents

Abstract

A cosmetic composition with tabebuia avellanedae extract is provided to suppress biosynthesis of prostaglandin E2(PGE2),which is related to inflammation, and generation of erythema caused by ultraviolet irradiation. A cosmetic composition with tabebuia avellanedae extract comprises 0.001-30.0wt% of tabebuia avellanedae extract as an active composition. The tabebuia avellanedae extract is extracted by purified water, a C1-C4 anhydrous alcohol, acetone, glycerine, butylene glycol, propylene glycol, dichloromethane, hexane, or benzene. The cosmetic composition can be a flexible toner, lotion, moisturizing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, or a cleansing water.

Description

The cosmetics composition being contained Pau d'Arco, Tabebuia avellanedae extracts and having the effects of antiphlogistic and abirritation of skin}

The present invention is Tahibo ( Pau) d'Arco , Tabebuia avellanedae ) extract as an active ingredient, anti-inflammatory and skin irritation by inhibiting biosynthesis of prostaglandin E2 (PGE2) related to inflammatory effects, reducing skin irritation by lactic acid, and inhibiting erythema production by UV irradiation The present invention relates to a cosmetic composition exhibiting alleviating efficacy.

The skin covers the entire surface of the body, serves to protect the internal organs from the external environment and irritation, and plays an important role as a barrier against moisture evaporation and blocking the ingress of foreign substances from the outside. However, the skin is a part of the body that is always directly exposed to the external environment, and the skin is constantly exposed to increased UV radiation, stress, and harmful chemicals due to the destruction of the ozone layer, thereby reducing the activity of keratinocytes and fibroblasts of the skin, and collagen synthesis. Decreased ability and elastin synthesis ability, decreased water retention capacity, increased dry skin, reduced defense ability against external infectious agents, etc. makes it sensitive to external stimuli.

Recently, more and more people are complaining of skin irritation such as erythema, swelling, acne, and itching, thereby reducing skin irritation and inflammation caused by various irritants, and in particular, synthetic surfactants contained in detergents and cosmetics. To reduce the skin irritation due to frequent use, it has been urgently required to develop an anti-inflammatory and skin irritant effect that can reduce the skin side effects of modern people.

Conventionally, various methods for alleviating skin irritation have been attempted, for example, a method for removing a substance causing skin irritation has been attempted. However, this research is limited because the functional raw material itself often acts as a stimulus source. For example, lactic acid, glycolic acid, salicylcic acid, retinoids, etc. are contained in cosmetics to promote skin cell regeneration or anti-wrinkle effects but cause skin irritation. . Accordingly, in recent years, many studies have been conducted to relieve stimulation by neutralizing acidity by adding strong alkalis such as NaOH or KOH to stimulus-inducing functional raw materials, but such a prescription has a problem of lowering the efficacy of existing raw materials.

In recent years, studies have been conducted on methods for suppressing intercellular immune-inducing substances, such as neuropeptides such as calcitonin gene-related peptide (CGRP) and substance P (sunstance P), which are secreted from neurons, Various cytokines and PGE2 are involved in edema formation and vasodilation in skin cells and immune cells, such as kinins such as bradykinin, which are activated by stress in tissues or plasma. It is known to act as a neuropeptide antagonist, such as substance P, bradykinin antagonist, COX inhibitors have been suggested as a substance that can reduce the skin inflammation and irritation, but did not show a clear effect.

On the other hand, when looking at the cosmetics for stimulation alleviation of the skin irritation cosmetic composition due to ultraviolet rays using a vitamin complex (Korean Patent Publication No. 2000-0058730), an external composition for skin containing raspberry leaf or fruit extract (Korea Patent Publication No. 03 -0015654), cosmetic composition containing phytosterol (Public Patent No. 2002-0063987), etc., and look at the case of using Tahibo in cosmetics, the case was used to improve wrinkles utilizing the collagen synthesis promoting effect of Tahibo extract (Korean Patent Publication No. 2004-0090255).

However, the composition containing the Tahibo extract is not known for improving the skin condition through anti-inflammatory action and skin irritation relief.

Accordingly, it is an object of the present invention to provide a cosmetic composition for skin irritation relief or anti-inflammatory.

In order to easily achieve the above objects as well as other objects that are easily expressed, the present inventors have conducted studies on active ingredients that improve skin conditions through anti-inflammatory and alleviation of skin irritation. And it has been found that there is an inhibitory effect of PEG2 involved in inflammation, there is an effect of alleviating skin irritation by lactic acid (lactic acid) contained in the cosmetics and completed the present invention.

The present invention was able to obtain the anti-inflammatory and skin irritant effect utilizing the production inhibitory activity of the prostaglandin of Tahibo extract, cytotoxicity relief, anti-inflammatory effect, efficacy of inhibiting erythema production by ultraviolet irradiation.

The present invention is described in more detail as follows.

The present invention relates to a cosmetic composition for anti-inflammatory and skin irritation relief using Tahibo extract, Tahibo extract is characterized in that it contains 0.001 to 30.0% by weight based on the total weight of the composition.

Taheebo (Taheebo) used in the present invention is a tree of Jacaranda ( Taebuia Avellanedae) , which grows only in a part of the Amazon, and has been called Tahibo in the ancient Inca empire in the sense of “god's favored medicine”, ancient Inca. Imperial Indians said they enjoyed this table of tea for their health. The history of Tahibo is 1,500 years ago, when the ancient Inca empire indigenous peoples had excellent sterilizing power that prevented the growth of mushrooms and fungi in the Tahibo medicinal plant. It has been used as a cure. Sometimes it is said to have been treated as valuable so that it was bartered for gold with neighboring countries. The Tabevia genus is native to more than 100 varieties in South America, but especially in parts of South America, Brazil. It is a tree of 30 m high with red-purple flowers and a large tree with a stem diameter of 50 cm to 1.5 m. It becomes the raw material of. As used herein, the term 'tahibo extract' refers to an extract obtained from leaves, flowers, stems, and roots of Tahibo, and preferably means an extract obtained from the inner bark portion of Tahibo.

The tahibo extract included in the cosmetic composition of the present invention can be obtained by various extraction methods, for example, solvent extraction, that is, as an extraction solvent, purified water, anhydrous alcohols having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol), Acetone, ethyl acetate, chloroform, glycerin, butylene glycol, propylene glycol, dichloromethane, hexane, benzene and the like can be extracted using a mixture of one or more selected. The ratio of the solvent and the tahibo pulverized product is 1: 5 to 1:30, and preferably 1:20 is best. It is extracted by immersing in an extractor at 15-45 ° C. for 7-15 days, or extracted at 40 ° C.-100 ° C. for 5-20 hours, and concentrated under reduced pressure or lyophilization.

However, it will be apparent to those skilled in the art that the solvent used in the extraction method of the present invention is not limited to the above-mentioned extraction solvent, and that Tahibo extract having substantially the same effect can be obtained using other extraction solvents.

On the other hand, the Tahibo extract is characterized in that it contains 0.001 to 30.0% by weight based on the total weight of the cosmetic composition. Preferably it is 0.1-10.0 weight%. When the content of the Tahibo extract is less than 0.001% by weight, it is difficult to expect the effect, when it exceeds 30.0% by weight does not appear to increase the apparent effect of increasing the content.

The active ingredient included in the cosmetic composition of the present invention is a tahibo extract, and in addition to the ingredients commonly used in cosmetic compositions, such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings, such as conventional ingredients such as .

Anti-aging cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing And the like, but are not limited thereto.

In case the formulation of the composition of the present invention is a paste, cream or gel, the carrier component is animal oil, vegetable oil, wax, paraffin, starch, trakant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or the like. This can be used.

In addition, when the formulation of the composition of the present invention is a solution or an emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene. Fatty acids esters of glycols, 1,3-butylene glycols, oils, glycerol aliphatic esters, polyethylene glycols or sorbitan.

When the formulation of the composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular, in the case of a spray, additionally chlorofluorohydrocarbon, Propellants such as propane / butane or dimethyl ether.

When the formulation of the composition of the present invention is a suspension, suspensions such as liquid diluents such as water, ethanol or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester are used as carrier components. Firstly, microcrystalline cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.

When the formulation of the composition of the present invention is a surfactant-containing cleansing agent, as a carrier component, an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid Amide ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.

The cosmetic composition of the present invention has an anti-inflammatory and skin stimulating effect. This is to improve the skin problem through the immune-inducing substance and edema inhibition, skin irritation relief effect that Tahibo extract has. Accordingly, the present invention is construed to include anti-aging, wrinkle improvement, moisturizing and skin elasticity use.

Hereinafter, the present invention will be described in more detail with reference to the following examples. These examples are only for illustrating the present invention in more detail, and the scope of the present invention is not limited to these examples according to the gist of the present invention to those skilled in the art to which the present invention pertains. Will be self explanatory.

Production Example  One : From Tahibo  Preparation of Extract

1 kg of Taheebo-Japan (manufactured by a Japanese company) is washed with clean water and dried in a cool shade. Thereafter, using a grinder to finely crush the dry Tahibo, 1 kg of the pulverized product is placed in an extractor equipped with a cooling capacitor, 5 liters of purified water is added and heated at 75 ° C. for 15 hours to extract hot water. The extract was filtered with a 400 mesh filter cloth, and the filtrates were collected and concentrated using a distillation apparatus equipped with a cooling condenser to completely evaporate the solvent to obtain a dry weight of 40.7 g of Tahibo extract.

Production Example  2-14: Preparation of extract for each solvent

Except for only the extraction solvent, Tahibo extract was obtained in the same manner as in Example 1, and the yield is shown in Table 1.

Production Example Extraction solvent Dry weight (g) 2 Methanol 38.5 3 ethanol 36.1 4 Butylene glycol 38.0 5 Propylene glycol 40.2 6 Butanol 39.1 7 Propanol 37.2 8 Ethyl acetate 28.2 9 chloroform 25.1 10  Acetone 26.7 11 glycerin 37.1 12 Hexane 19.3 13 benzene 17.4 14 Dichloromethane 18.3

Experimental Example  1: prostaglandin E2  ( PGE2 ) Inhibitory effect

To investigate the effect of Tahibo extract on the biosynthesis of prostaglandins, mouse macrophage lines, RAW264.7 cells, were divided into 5 × 10 ⁴ cells in 96-well test plates for 24 hours in medium containing 10% fetal bovine serum. Incubated. Aspirin was then added to a final concentration of 500 μM to inhibit the activity of prostaglandin biosynthetic activity (prostaglandin H2 synthetase, or cyclooxygenase) remaining in the cells. Two hours after aspirin treatment, each well containing RAW264.7 cells was washed twice with PBS, and 200 μl of 10% FBS-DMEM medium containing 1 μg / ml LPS (lipopolysaccharide) was added to each well (control). In medium without LPS). Then, the tahibo extract of the preparation was treated to a final concentration of 10 ppm, and then incubated for 16 hours. By taking an appropriate amount of the culture supernatant and quantifying biosynthesized PGE2 for 16 hours, the prostaglandin inhibitory effect of the tahibo extract was determined. The amount of PGE2 was measured and quantified by ELISA reader 450 nm and the results are shown in Table 2 below.

sample PGE2 production amount (pg / 10 ⁵ cells) Inhibition Rate (%) Negative Control 25.3 ± 8.2 - LPS 266.3 ± 10.3 - Preparation Example 1 + LPS 109.9 ± 12.1 64.9 Preparation Example 2 + LPS 83.9 ± 9.6 75.7 Preparation Example 3 + LPS 77.2 ± 9.1 78.5 Preparation Example 4 + LPS 89.3 ± 9.1 73.4 Preparation Example 5 + LPS 90.4 ± 3.8 73.0 Preparation Example 6 + LPS 101.2 ± 12.5 68.5 Preparation Example 7 + LPS 101.7 ± 10.1 68.3 Preparation Example 8 + LPS 89.1 ± 8.3 73.5 Preparation Example 9 + LPS 95.1 ± 11.0 71.0 Preparation Example 10 + LPS 140.3 ± 9.7 52.3 Preparation Example 11 + LPS 150.0 ± 7.8 48.3 Preparation Example 12 + LPS 203.3 ± 6.1 26.1 Preparation Example 13 + LPS 199.8 ± 6.6 27.3 Preparation 14 + LPS 207.0 ± 10.4 24.6 Calculated based on the difference in PGE2 production between negative and positive controls

As a result of the experiment, the Tahibo extract of Preparation Example 3 using ethanol as the extraction solvent showed the most excellent anti-inflammatory effect as shown in Table 2.

Experimental Example  2: cytotoxic effect test

Fibroblasts (Human fibroblast) to be cultured in the medium dispensed by containing 10% fetal calf serum to 5x10 ⁴ cells per well of a 96 well plate (96-well plate) for 24 hours. Subsequently, fetal calf serum-free medium was replaced, and the extracts obtained in Preparation Examples 1 to 14 were added to a final concentration of 100 ppm in the culture medium, followed by 4 hours of .02% sodium dodecyl sulfate (SDS). ) Was added and incubated for 24 hours. After incubation, 10 μl of a 5 mg / ml yellow tetrazolium salt (MTT) solution was added per well, and after 4 hours, the yellow tetrazolium salt solution was removed, and dimethyl sulfoxide (DMSO) was added 100 μl per well. Next, the solution was dissolved for 10 minutes and the absorbance of 570 nm was measured using a spectrophotometer (Molecular Devices, USA). The results are shown in Table 3 below.

sample Cell survival rate (%) Negative Control 100.0 SDS 5.3 Preparation Example 1 + SDS 100.2 Preparation Example 2 + SDS 101.5 Preparation Example 3 + SDS 112.3 Preparation Example 4 + SDS 107.5 Preparation Example 5 + SDS 99.4 Preparation Example 6 + SDS 101.2 Preparation Example 7 + SDS 106.5 Preparation Example 8 + SDS 105.4 Preparation Example 9 + SDS 103.0 Preparation Example 10 + SDS 85.2 Preparation Example 11 + SDS 87.1 Preparation Example 12 + SDS 60.7 Preparation Example 13 + SDS 55.4 Preparation Example 14 + SDS 54.9

As a result of the experiment, the Tahibo extract of Preparation Example 3 using ethanol as the extraction solvent showed the best cytotoxicity mitigating effect, as shown in Table 3 below, the preparation of Example 14 shows the lowest cytotoxicity mitigating effect gave.

Experimental Example  3: through animal experiment Tahibo  Anti-inflammatory Effect Experiment of Extract

In order to examine the anti-inflammatory effect on the Tahibo extract, ICR mice were divided into three groups of five mice each, and test group 1 was obtained by using 1.0% of extract of preparation 3 + 99% of ethanol as a sample, 2.0% of extract of preparation 3 + ethanol 98 % Was used as a sample and only negative ethanol was used as a negative control.

Using both ears of each group of ICR mice as the test site, the ears were washed clean with ethanol before applying the sample, and the average thickness of the ears was measured by micrometer. 20 μl of the sample was applied to each test group, and after 1 hour, 2 mg / ear of arachidonic acid was applied to the right ear. After 1 hour, the ear edema was micrometered on both ears three times. Repeated measurements were taken. The left ear was used to determine whether the inflammation was induced, and the anti-inflammatory effect was determined based on the control group treated with ethanol as shown in Equation 1 below, and the result (average value of each group) is shown in Table 4 below. It was.

(Equation 1)

Inhibition rate of inflammation (%) = (A-B) / A × 100

A: Change of control ears (ear thickness after arachidonic acid treatment-ear thickness before arachidonic acid treatment)

B: Change of Ear in Sample Treatment Group (Thickness of Ear after Arachidonic Acid Treatment-Ear Thickness after Arachidonic Acid Treatment)

division Ear thickness (㎛)  Inhibition Rate (%) Before arachidonic acid treatment After arachidonic acid treatment Thickness change Control 325 543 218 Test Group 1 (Tahibo Extract 1.0%) 323 480 157 28.0 Test Group 2 (Tahibo Extract 2.0%) 316 457 141 35.3

As can be seen from the results in Table 4, it was found that the Tahibo extract inhibits the inflammatory response induced by Arikidonic Acid, which is also effective in vivo.

Experimental Example  4: skin Patch test  through Tahibo  Stimulation Relaxation Effect Test of Extracts

Lactic acid, a skin irritant included in the formulation of Table 5, was tested through human skin patch tests on 20 women in their 20s and 30s who had no hypersensitivity to skin irritation due to past history and have no skin disease or skin allergy symptoms. Lactic acid) was confirmed to reduce the irritation effect of Tahibo extract against 5.0%. First the test site was wiped with 70% ethanol and dried. 15 μg of the test substance prepared in the composition of Table 5 was added dropwise into a Fin chamber (Finn chamber, 100 × 10, EPITEST, Finland), and then sealed in the forearm inner part of the test subject. The patch was marked for 24 hours, the patch was removed, and the test site was marked with a pen. After 1 hour and 24 hours after marking, the test site was observed using a magnifying glass (8MC-150, DAZOR, United States of America) to observe erythema and edema. Skin response was determined according to the regulations of the International Contact Dermaitis Research Group (ICDRG), and the mean skin response rate was calculated according to Equation 2. The results are shown in Table 6.

ingredient Example 1 (% by weight) Example 2 (% by weight) Comparative Example 1 (% by weight) Comparative Example 2 (wt%) Preparation Example 3 2.5 5.0 Lactic acid 5.0 5.0 5.0 Beeswax 1.0 1.0 1.0 1.0 Polysorbate 60 0.5 0.5 0.5 0.5 Liquid paraffin 10. 10.0 10.0 10.0 Squalane 3.0 3.0 3.0 3.0 Sorbitan stearate 1.0 1.0 1.0 1.0 Glyceryl Stearate 1.5 1.5 1.5 1.5 Stearic acid 1.5 1.5 1.5 1.5 glycerin 5.0 5.0 5.0 5.0 Propylene glycol 5.0 5.0 5.0 5.0 Caroxyvinyl Polymer 0.1 0.1 0.1 0.1 Triethanolamine 0.1 0.1 0.1 0.1 antiseptic a very small amount a very small amount a very small amount a very small amount Purified water Remaining amount Remaining amount Remaining amount Remaining amount system 100 100 100 100

[Evaluation Criteria and Score of Skin Response]

Symbol score Evaluation standard - 0 No response ± 0.5 Faint or light erythema  +  One Boundary but weak erythema, edema and papules  ++ 2 Pronounced erythema, papules and vesicles  +++ 3 Severe erythema and alveolar, scleroderma

Equation 2

Average skin reactivity = (score x responses x 100 x 1/2) / [3 (maximum score) x total subjects (n)]

Test substance After 1 hour After 24 hours Reactivity (%) (n = 20)  ± + ++ ± + ++ Example 1 4 - - - - - 1.66 Example 2 2 - - - - - 0.83 Comparative Example 1 12 2 - 7 One - 10.42 Comparative Example 2 - - - - - - 0.00

As can be seen in Table 6, in the skin patch test, strong skin irritation was observed in Comparative Example 1 containing lactic acid, and in Example 1 and Example 2, it showed a stimulating alleviation effect, and the concentration-dependent most in Example 2 It showed an excellent stimulating effect.

Experimental Example  5: Human testing  Inhibition of erythema formation upon UV irradiation

A hole with a diameter of 1.5 cm in the upper arm of a subject of 20 healthy males who had not taken nonsteroidal anti-inflammatory drugs and other steroid preparations to evaluate the effects of Tahibo extract on UV-induced skin erythema induction. After attaching the four opaque tapes, the erythema was induced by irradiating ultraviolet light (UVB) twice as much as the minimum erythema dose (MED) of each subject. The formulations prepared according to Table 7 were applied 1 hour before and immediately after UV irradiation. The erythema index was assessed after 6 hours and 24 hours after erythema index. The erythema formation was measured by using a chromatic chromaticity (Chromameter CR 300, Minolta) and a * color parameters. It was evaluated as severe. The result was an average value, and the results are shown in Table 8 below.

ingredient Example 3 (% by weight) Example 4 (% by weight) Comparative Example 3 (wt%) Preparation Example 3 2.5 5.0 Beeswax 1.0 1.0 1.0 Polysorbate 60 0.5 0.5 0.5 Liquid paraffin 10. 10.0 10.0 Squalane 3.0 3.0 3.0 Sorbitan stearate 1.0 1.0 1.0 Glyceryl Stearate 1.5 1.5 1.5 Stearic acid 1.5 1.5 1.5 glycerin 5.0 5.0 5.0 Propylene glycol 5.0 5.0 5.0 Caroxyvinyl Polymer 0.1 0.1 0.1 Triethanolamine 0.1 0.1 0.1 antiseptic a very small amount a very small amount a very small amount Purified water Remaining amount Remaining amount Remaining amount system 100 100 100

Composition Erythema index 6 hours later After 24 hours Example 3 6.8 6.2 Example 4 6.3 5.8 Comparative Example 2 8.1 7.7

As can be seen from the results of the table, it was shown that the formulation containing the Tahibo extract has an effect of inhibiting erythema production by ultraviolet rays, and the inhibitory effect was concentration-dependent.

Hereinafter, examples of the cosmetic formulation of the present invention include a flexible lotion, an essence, a pack, a shampoo, a body cleanser, and the like, which contain tahibo extract, but the formulation of the cosmetic of the present invention is not necessarily limited thereto.

Formulation example  1: skin lotion

Skin lotion containing the Tahibo extract of Preparation Example 3 obtained above was prepared according to a conventional method in the composition of Table 9.

Raw material name Content (% by weight) Preparation Example 3 5.0 1,3-butylene glycol 5.2 Oleyl alcohol 1.5 ethanol 3.2 Polysorbate 20 3.2 Benzophenone-9 2.0 Carboxyl Vinyl Polymer 1.0 glycerin 3.5 incense a very small amount antiseptic a very small amount Purified water Remaining amount system 100

Formulation example  2: lotion

A lotion containing the tahibo extract of Preparation Example 3 obtained above was prepared according to a conventional method with the composition of Table 10 below.

Raw material name Content (% by weight) Preparation Example 3 5.0 Cetostearyl alcohol 1.0 Glyceryl Monostearate 0.8 Sorbitan monostearate 0.3 Polysorbate 60 1.0 Mineral oil 5.0 Pyromethicone 3.0 Dimethicone 0.5 Allantoin 0.1 glycerin 5.0 Alcohol 2 Propylene glycol 3.0 incense a very small amount antiseptic a very small amount Purified water Remaining amount system 100

Formulation example  3: essence

Essence containing the Tahibo extract of Preparation Example 3 obtained above was prepared according to a conventional method in the composition of Table 11.

Raw material name Content (% by weight) Preparation Example 3 5.0 1,3-butylene glycol 4.0 glycerin 3.0 Allantoin 0.5 Panthenol 0.1 EDTA-2Na 0.01 ethanol 5.0 Triethanolamine 1.5 Squalane 2.0 Beeswax 2.5 Polysorbate 60 3.5 Carboxyl Vinyl Polymer 1.0 Sorbitan sesquioleate 2.5 incense a very small amount antiseptic a very small amount Purified water Remaining amount system 100

Formulation example  4: pack

The pack containing the Tahibo extract of Preparation Example 3 obtained above was prepared according to a conventional method with the composition of Table 12 below.

Raw material name Content (% by weight) Preparation Example 3 5.0 Ethyl alcohol 3.0 EDTA-2Na 0.05 Propylene glycol 5.0 Glyceline 4.5 Cabopol 1.5 Polyoxide 0.2 antiseptic a very small amount incense a very small amount Purified water Remaining amount system 100

Formulation example  5: Massage cream

Massage cream containing the Tahibo extract of Preparation Example 3 obtained above was prepared according to a conventional method in the composition of Table 13.

Raw material name Content (% by weight) Preparation Example 3 5.0 glycerin 4.0 Vaseline 3.5 Triethanolamine 0.5 Liquid paraffin 24.0 Squalane 3.0 Beeswax 2.1 Tocopheryl Acetate 0.1 Polysorbate 60 2.4 Carboxyl Vinyl Polymer 1.0 Sorbitan sesquioleate 2.3 incense a very small amount antiseptic a very small amount Purified water Remaining amount system 100

Formulation example  6: shampoo

Shampoo containing the Tahibo extract of Preparation Example 3 obtained above was prepared according to a conventional method in the composition of Table 14.

Raw material name Content (% by weight) Preparation Example 3 5.0 Alkyl sulfate (30%) 25.0 Alkyl ether sulfate (30%) 20.0 Alkylamidobetaine (30%) 5.0 Propylene glycol 3.0 Lauramid 4.0 EDTA-2Na 0.1 Polyquaternium-10 0.05 NaCl 0.1 Citric acid 2.4 incense a very small amount antiseptic a very small amount Purified water Remaining amount system 100

Formulation example  7: Body cleanser

A body cleanser containing the Tahibo extract of Preparation Example 3 obtained above was prepared according to a conventional method with the composition of Table 15 below.

Raw material name Content (% by weight) Preparation Example 3 5.0 Alkyl ether saccharide (30%) 30.0 Alkyl ether sulfosuccinate (30%) 20.0 Alkylamidobetaine (30%) 5.0 Propylene glycol 5.0 Betaine 5.0 Lauramiddiei 4.0 Cellulose gum 0.05 Hydrolyzed protein 0.1 Citric acid a very small amount NaCl a very small amount incense a very small amount antiseptic a very small amount Purified water Remaining amount system 100

Claims (7)

A cosmetic composition comprising tahibo extract as an active ingredient and having anti-inflammatory and skin irritation efficacy. The cosmetic composition according to claim 1, wherein the tahibo extract has anti-inflammatory and skin irritation efficacy by inhibiting the production of prostaglandins. The cosmetic composition of claim 1, wherein the tahibo extract has anti-inflammatory and skin stimulating effects by alleviating skin irritation by lactic acid. The cosmetic composition according to claim 1, wherein the tahibo extract has anti-inflammatory and skin irritation efficacy by inhibiting erythema production by ultraviolet rays. The cosmetic composition of claim 1, wherein the tahibo extract contains 0.001 to 30.0 wt% based on the total weight of the composition. The pure water of claim 1, wherein the tahibo extract is one pure water selected from a solvent group including purified water, anhydrous alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, chloroform, glycerin, butylene glycol, propylene glycol, dichloromethane, hexane, and benzene. Cosmetic composition, characterized in that by using a solvent or a mixed solvent of two or more selected arbitrarily selected from the combination, the selected extraction solvent is added in an amount of 10 to 30 times the weight of the Tahibo. 7. The composition of claim 1, wherein the composition is from the group consisting of softener, nourishing lotion, nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray and powder Cosmetic composition, characterized in that it has a formulation selected.